Appropriate Drug Use for Children: What a Medical Doctor Must Know When Using an Unapproved or Off-label Drug
نویسندگان
چکیده
منابع مشابه
When Are Medical Apps Medical? Off-Label Use and the Food and Drug Administration
People have a love/hate relationship with rapidly changing healthcare technology. While consumer demand for medical apps continues to grow as rapidly as does supply (there are over 100,000 health, wellness and medical applications, or ‘apps’ on the market), healthcare professionals and safety experts worry about the impact of these apps on the health consumer. In response to the rapidly growing...
متن کاملWorsening Clinical Outcome with Increasing Number of So-Called Off-Label or Unapproved Indications for Use of Drug Eluting Stents
Objective: We explored the impact of increasing number of off-label patient and lesion characteristics on 5-year clinical outcome following implantation of first generation drug eluting stents. Furthermore we tried to assess if stent performance might be improved if the off-label characteristics present were taken into account to guide the stent brand selection. Design: A total of 2888 coronary...
متن کاملOff-label drug use: author's reply.
The authors have stated that the accuracy of dose was checked from standard neonatal formularies, viz. British National Formulary 2005 and Neofax 2008, and stated that 75% of medications were not approved by FDA for neonatal use. They have not mentioned the document or the source that they relied upon to classify the drug as off-label or otherwise. It may not be advisable to decide if use of a ...
متن کاملAutomated Detection of Off-Label Drug Use
Off-label drug use, defined as use of a drug in a manner that deviates from its approved use defined by the drug's FDA label, is problematic because such uses have not been evaluated for safety and efficacy. Studies estimate that 21% of prescriptions are off-label, and only 27% of those have evidence of safety and efficacy. We describe a data-mining approach for systematically identifying off-l...
متن کاملOff-label use of drug-eluting stents.
ince Food and Drug Administration (FDA) approval of he first drug-eluting stent (DES) in April 2003, their use ncreased to 90% of all coronary stent procedures in the U.S. y 2006 (1). With restenosis virtually eliminated, DES were pplied to increasingly more complex coronary lesions. owever, over the past few years, reports of late stent hrombosis began to emerge. Additional reports of late ste...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pediatric Cardiology and Cardiac Surgery
سال: 2014
ISSN: 0911-1794
DOI: 10.9794/jspccs.30.498